DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Huntington's Disease

Intervention: Tetrabenazine (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: The University of Texas Health Science Center, Houston

Overall contact:
William G Ondo, MD, Phone: 832-325-7446, Email: william.ondo@uth.tmc.edu

Summary

The purpose of this research study is to see if tetrabenazine, which is commonly used to treat Huntington's Disease (HD), reduces the problems of impulsivity that are common in patients with HD. Investigators will also see how the medicine affects aspects of thinking and mood.

Clinical Details

Official title: A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Change in Score on the Questionnaire for Impulsive Disorders in Parkinson's Disease

Change in Score on the Geriatric Depression Scale

Change in Score on the Barrat Impulsivity Scale

Change in Score on the Minnesota Impulsivity Disorders Interview

Change in Score on the Iowa Gambling Task

Change in Score on the Montreal Cognitive Impairment Assessment

Secondary outcome: Change in Score on the United Huntington's Disease Rating Scale - Motor section

Detailed description: This study is an open-label assessment of behavioral symptoms including depression, impulsivity, and suicidal ideations in patients prior to, and after, taking a stable dose of TBZ. Once a subject has provided written informed consent, he/she will be scheduled for a study visit. All subjects will be evaluated with tests of depression (Geriatric Depression Scale), impulsivity (Minnesota Impulsivity Scale, QUIP, BIS-11, and computerized impulsivity scales), and suicidal ideation (Columbia Suicide Scale) as a safety measure before they actually start taking TBZ. Patients will be asked to return to the clinic for an identical evaluation plus adverse events, after they have been on a stable dose of TBZ for 4 weeks, which would be 7 ± 1 week after initiating TBZ. Patients will be titrated over 2- 4 weeks to best dose as determined by the investigator, up to a maximum of 75 mg/day. In our clinical practice, >90% of HD patients take 75mg or less per day. This also allows for a more consistent and shorter titration period to improve patient retention. As patients are titrating, there will be several telephone contacts conducted. The initial dose will be 12. 5 mg BID. Best dose will be largely determined by adverse events. Determination of best dose will include one scheduled phone call and others as needed. Other medications will remain stable between visits.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- For HD patients only--Definite HD (positive gene testing or typical symptoms in the

context of family history of HD).

- A moderate degree of impulsivity as measured by the Barrat Impulsivity Scale (BIS).

(>65)

- Must be symptomatic in the opinion of the investigator. We will employ the standard

clinical criteria for symptomatic HD, any motor signs c/w HD, usually chorea).

- Patient is cognitively alert and able to answer/understand.

Exclusion Criteria:

- Patient requires the assistance of another person to walk, or is non-ambulatory.

- Patient is severely impaired cognitively.

- Patients taking neuroleptic (dopamine blocking) medications within the past 14 days.

- patient is actively suicidal, has untreated or inadequately treated depression, has

impaired hepatic function, is taking MAO inhibitors or is taking reserpine or has been off of reserpine for less than 20 days

Locations and Contacts

William G Ondo, MD, Phone: 832-325-7446, Email: william.ondo@uth.tmc.edu

University of Texas Health Science Center at Houston, Houston, Texas 77030, United States; Recruiting
William Ondo, MD, Phone: 832-325-7446, Email: william.ondo@uth.tmc.edu
Additional Information

Starting date: April 2014
Last updated: July 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017